About this item:

569 Views | 585 Downloads

Author Notes:

Corresponding author. vmaster@emory.edu

Peer review under responsibility of Second Military Medical University.

The authors declare no conflict of interest.


Research Funding:

Rishi R. Sekar was awarded the American Urological Association/Urology Care Foundation Herbert Brendler Medical Student Summer Research Fellowship to perform this work.

He is also supported in part by PHS Grant ULTR000454 from the Clinical and Translational Science Award Program, National Institutes of Health, National Center for Advancing Translational Sciences.

Brian P. Pollack is supported by the Winship Cancer Institute Melanoma and Skin Cancer Fund and the Atlanta VA Medical Center.

These funding sources were not involved in the development of the study; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.


  • Biomarker
  • MHCI
  • Prognosis
  • Renal cell carcinoma

Major histocompatibility complex i upregulation in clear cell renal cell carcinoma is associated with increased survival

Show all authors Show less authors


Journal Title:

Asian Journal of Urology


Volume 3, Number 2


, Pages 75-81

Type of Work:

Article | Final Publisher PDF


Objective To examine the prognostic value of tumor major histocompatibility complex I (MHCI) expression on survival and recurrence in patients with clear cell renal cell carcinoma (RCC). Methods Fifty-three patients that underwent nephrectomy at our institution for clear cell RCC (T1-T3) with ≥4 years of follow-up were queried from our nephrectomy database. Immunohistochemical staining for MHCI was performed on tumor specimens and MHCI expression was quantified with an automated image analysis technique. Patients were divided into high and low MHCI expression groups in order to study the relationship between MHCI expression and prognosis using the Kaplan-Meier method and log-rank test. Results Overall survival and recurrence free survival were increased in the high MHCI expression group compared to the low MHCI expression group (log-rank, p = 0.036 and p = 0.028, respectively). Patients alive at the end of the study had higher MHCI expression (mean positivity score 0.82) than those that died of disease (mean positivity score 0.76, t test, p = 0.030). Patients that did not develop recurrence during the study period had higher MHCI expression (mean positivity score 0.83) than those that did develop recurrence (mean positivity score 0.78), but this difference was not significant (t test, p = 0.079). Conclusion Our data demonstrate that high MHCI expression confers improved overall and recurrence free survival in patients with clear cell RCC and could serve as an important prognostic tool in identifying high-risk patients.

Copyright information:

© 2016 Editorial Office of Asian Journal of Urology.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote